 SAN DIEGO, March 20, 2021 PRNewswire -- Neurocrine Biosciences, Inc. Nasdaq: NBIX today announced that it will present additional positive data from its Phase II CAHlibrate study of crinecerfont, an investigational, oral, non-steroidal corticotropin-releasing factor type 1 CRF1 receptor antagonist for the potential treatment of classic congenital adrenal hyperplasia CAH due to 21-hydroxylase deficiency 21-OHD, at ENDO 2021, the Endocrine Societys annual meeting, on March 2023, 2021. These new analyses, based on data from seven male subjects with classic CAH receiving crinecerfont, demonstrate dose-dependent decreases in androstenedione A4, a key marker of CAH control and precursor to testosterone, with similar dose-dependent decreases in the A4 to testosterone ratio. 